Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Simonson PD, Kim KH, Winston-McPherson G, Parakh RS, Yamaguchi D, Merrill AE, et al. Characterization of bilirubin interference in three commonly used digoxin assays. Clin Biochem. 2019;63:102-105.

Falzone ME, Rheinberger J, Lee B-, Peyear T, Sasset L, Raczkowski AM, et al. Structural basis of Ca-dependent activation and lipid transport by a TMEM16 scramblase. Elife. 2019;8.

Starza ID, De Novi LA, Santoro A, Salemi D, Tam W, Cavalli M, et al. Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemia. Leuk Lymphoma. 2019;60(11):2838-2840.

Choi S, Wang D, Chen X, Tang LH, Verma A, Chen Z, et al. Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression. Mol Cancer. 2019;18(1):92.

Orleans RA, Magro CM, Varghese GI. A subcutaneous nodule on the mid back. JAAD Case Rep. 2019;5(3):252-254.

Crowe EP, DeSimone RA. Transfusion support and alternatives for Jehovah's Witness patients. Curr Opin Hematol. 2019;26(6):473-479.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, et al. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res. 2019;17(2):618-627.

Zhu H, Wang M, Dong Y, Hu H, Zhang Q, Qiao C, et al. Detection of non-criteria autoantibodies in women without apparent causes for pregnancy loss. J Clin Lab Anal. 2019;33(9):e22994.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, et al. Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. J Natl Compr Canc Netw. 2019;17(3):194-200.

Penchev VR, Chang Y-, Begum A, Ewachiw T, Gocke C, Li J, et al. Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma. Mol Cancer Res. 2019;17(4):929-936.